Ray Therapeutics, Inc.

United States - San Francisco, California

• 17/05/2023
• Series A
• $100,000,000

Ray Therapeutics Inc (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and will not require light-enhancing goggles). Our studies have shown for the first time that our proprietary ChRown optogenetic protein can restore high levels of visual acuity, contrast sensitivity and visual field.

RayTx lead asset, RTx-015, is expected to address the huge unmet medical in people suffering from many forms of retinal blindness (independent of the underlying genetic cause), including those with advanced age-related macular degeneration. RayTx has partnered with a world-leading AAV gene therapy manufacturer is utilizing their proprietary commercial manufacturing process and analytics to maximally de-risk clinical development. RayTx anticipates clinical trials will begin by the end of 2023 in our initial indication, retinitis pigmentosa.

Related People

Paul BresgeCo Founder

United States - San Francisco, California

Paul Bresge has been a leader in the cell and gene therapy biotech space for over a decade. He is co-founder and Chief Executive Officer at Ray Therapeutics, an optogenetics gene therapy company for blinding diseases. Prior to co-founding Ray Therapeutics, Paul served as Chief Executive Officer at jCyte, a late-stage clinical cell therapy company developing a treatment for retinitis pigmentosa. He was involved with jCyte prior to its inception in 2012 and concluded a $252M licensing deal with Santen Pharmaceutical in 2020. In addition to his current role as CEO, Paul is on the board of directors of Healios, an iPSC company with programs in ophthalmology and oncology, and is a mentor on the Winning Pitch Challenge. Paul is passionate about supporting companies with emerging technologies that have great potential to address unmet needs for patients with blinding and other diseases.

LinkedIn https://www.linkedin.com/in/paulbresge/